In this review article, we discuss the currently available pre-clinical and clinical data of emavusertib, a selective, orally bioavailable IRAK-4 inhibitor in the treatment of R/R B-cell lymphomas and myeloid malignancies. This evidence concerns the gene IRAK4 and B-cell non-Hodgkin lymphoma.